| Identification | Back Directory | [Name]
CG-200745 | [CAS]
936221-33-9 | [Synonyms]
CG 2
CG-200745
CG 2 (HDAC inhibitor)
(E)-N-[3-(dimethylamino)propyl]-N'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide
2-Octenediamide, N1-[3-(dimethylamino)propyl]-N8-hydroxy-2-[(1-naphthalenyloxy)methyl]-, (2E)- | [Molecular Formula]
C24H33N3O4 | [MDL Number]
MFCD25976805 | [MOL File]
936221-33-9.mol | [Molecular Weight]
427.54 |
| Hazard Information | Back Directory | [Uses]
Ivaltinostat (CG-200745) is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat inhibits deacetylation of histone H3 and tubulin. Ivaltinostat induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat induces apoptosis and has anti-tumour effects[1][2][3][4]. | [in vivo]
Ivaltinostat (CG-200745; p.o.; 30?mg/kg/day; for 7 days) attenuates oxidative stress, inflammatory cytokines, and adhesion molecules in UUO kidneys[5]. | Animal Model: | Male 8-week-old C57BL/6?J mice weighing 20~22?g of unilateral ureteral obstruction (UUO)[5] | | Dosage: | 30?mg/kg | | Administration: | PO; daily; for 7 days | | Result: | Attenuated oxidative stress, inflammatory cytokines and adhesion molecules in UUO kidneys.
|
| [IC 50]
HDAC | [storage]
Store at -20°C | [References]
[1] Oh ET, et al. Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells. Invest New Drugs. 2012 Apr;30(2):435-42. DOI:10.1007/s10637-010-9568-2
[2] Hwang JJ, et al. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL. Invest New Drugs. 2012 Aug;30(4):1434-42. DOI:10.1007/s10637-011-9718-1
[3] Dawoon E Jung, et al. CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway. Sci Rep. 2017 Sep 7;7(1):10921. DOI:10.1038/s41598-017-11094-3
[4] Chun SM, et al. Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells. PLoS One. 2015 Mar 17;10(3):e0119379. DOI:10.1371/journal.pone.0119379
[5] Choi HS, et al. Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease. Sci Rep. 2018 Aug 1;8(1):11546. DOI:10.1038/s41598-018-30008-5 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310; |
| Website: |
https://www.weikeqi-biotech.com/ |
|